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ABSTRACT 
 
This research project investigated the topic of stem cells, from various types of stem cells 
through their effect on humanity. In the first two chapters, the different types of stem cells, and 
their uses and applications are described. The latter two chapters discuss the ethics and legalities 
that govern stem cell research among global societies. Through the research presented regarding 
types, applications, ethical considerations, and legal constraints, the authors of this IQP conclude 
that, armed with the right knowledge, stem cell research performed in an ethical manner is a 
technology that should continue to be funded and researched, as great potential of this science 
has already been proven, and it can potentially improve the quality of life or save the lives of 
millions. 
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PROJECT OBJECTIVES 
 
The objective of the research for this IQP project was to examine the topic of stem cell 
science and to discuss the effects of this new controversial technology on society as it continues 
to develop.  After a careful gathering and studying of this information, a conclusion will then be 
made by the authors regarding the use of stem cells, and which ethical and legal considerations 
best represent the authors‟ point of view. 
The purpose of Chapter-1 is to describe what classifications of stem cells exist and 
subsequently document the various types, where we isolate each type from, and their potencies.  
Chapter-2 will document a sample set of a few different examples of successful experimentation 
that stem cells have been used for, distinguishing animal experiments from human clinical trials, 
and providing examples of human testing and trials whenever possible while not undercutting the 
importance of animal research and experimentation.  The goal of Chapter-3 is to examine the 
ethics surrounding this controversial research topic, while Chapter-4 examines both the U.S. and 
international laws governing stem cell research and the bases on which these laws were 
developed. 
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Chapter-1: Stem Cell Types 
Sarah Nuccitelli 
 
For as long as there has been life, there have been various types of diseases.  While 
treatments have been discovered for many of these life altering disorders, many of them, like 
Parkinson's disease and diabetes, cannot yet be cured with medicine.  Stem cells are the so-called 
master cells of the body because they are undifferentiated cells used to create other types of cells. 
This means that they can repair damaged tissue to provide treatments for many different 
incurable diseases.  Due to this regenerative ability, they are being researched as possible 
treatments for specific diseases (About Stem Cells, 2010).  The hope is to use stem cells to treat 
some diseases by regenerating cells that have been damaged by aging or disease so function can 
be regained.  As a result, much research has been done regarding the use of stem cells as medical 
treatments.  But as the scientific community struggles to forge on with potential life saving 
research, there is much debate about whether some types of stem cells are ethically sound.  The 
fight between the scientific and the religious communities makes the stem cell issue seem black 
and white, but realistically many intricacies must be considered before any individual, or the 
general public, can take sides.  In the debate, one key point of misinformation is that all stem 
cells are alike.  In fact, stem cells come in many different types and potencies; all are unique and 
have different medical benefits.  It is important to understand the differences in stem cell types 
and potencies to be able to understand their ethics, so this is the purpose of this chapter. 
 
Stem Cell Potencies 
Although all stem cell types have the ability to regenerate damaged cells, they cannot do 
so equally as shown in Figure-1.  The differences between stem cell types lies in the fact that 
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some are harvested from embryos, some from adult tissues, some are specific and some hold 
endless potential.  From a broad perspective, all stem cells can be categorized into 4 different 
groups based on their potency.  Totipotent stem cells are found in early embryos (newly fertilized 
eggs through the 8-cell stage) (diagram upper left) and have the ability to form any type of tissue, 
including the placenta (History of Stem Cell Research, 2010).   Pluripotent stem cells are found 
in the inner cell mass of the blastocyst, and can form more than two hundred types of cells, not 
including the placenta.  Embryonic stem cells are pluripotent.  Multipotent stem cells have the 
ability to form groups of related types of cells.  For example, hematopoietic stem cells can form 
all the cellular components of blood, but do not usually form neurons.  Unipotent stem cells can 
only give rise to one specific type of cell lineage, usually reflecting the type of tissue the stem 
cell resides in (History of Stem Cell Research, 2010). 
 
 
Figure-1:  Diagram of Stem Cell Potencies.  Newly fertilized eggs 
through the 8-cell stage are totipotent.  Cells of the inner cell mass of a 
blastocyst (diagram upper right) are pluripotent.  Unipotent cells are 
found in specific tissues, and usually can create only that type of tissue.  
(Wikipedia.com) 
 
Stem cell potency has a lot to do with where the stem cells come from; cells from early 
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embryos, like embryonic stem cells, are more potent than those that are harvested from adults.  
Cells found in blastocysts have the ability to turn into almost any type of cell because they are 
not yet differentiated.  However, adult cells, like skin stem cells, can usually only make more 
skin cells (Adult Stem Cells, 2006).  Totipotent cells at the 1-8 cell stage decrease potency at the 
5-day blastocyst stage, and then have even less potential for stem cells residing in adult tissues.  
Overall, younger cells have a greater medical potential, and unfortunately these cells also have 
the greatest ethical problems. 
 
Embryonic Stem Cells 
Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of the 
five to seven-day old blastocyst (How Embryonic, 2010).  These cells are obtained from excess 
embryos from in vitro fertilization (IVF) clinics.  Although the IVF embryos were originally 
created for reproductive purposes, once a family has enough children, the parents can consent 
that their excess embryos be used for research purposes instead of being discarded.  At 5-7 days, 
the embryo is a blastocyst containing about 100 cells.  The ES cells are harvested from the inner 
cell mass (How Embryonic, 2010).  This process usually kills the embryo, but makes way for an 
enormous amount of medical potential.  Embryonic stem cells are favorable in the research 
community because they are relatively easy to isolate, can grow indefinitely, and have the 
potential to develop into any type of adult cell.   
ES cells were first isolated in 1981 from mouse embryos (Evans and Kaufman, 1981; 
Martin, 1981), and were isolated from human embryos in 1998 (Thomson et al., 1998).  Figure-2 
shows the process by which scientists obtain ES cells.  Embryos are created by IVF, then grown 
to the blastocyst stage (diagram left).  A micropipette is used to extract ES cells from the inner 
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cell mass, and the cells are co-cultured with mouse or human cells (diagram center) so that large 
quantities can be grown (diagram right).  Since ES cells are undifferentiated, they have the 
ability to turn into any type of other cell except the placenta.  To induce different types of 
differentiation, various growth factors are added to the medium to allow the formation of cells 
like red blood cells, epithelial cells, or muscle cells (How Embryonic, 2010). 
 
 
Figure-2:  Diagram of Embryonic Stem Cell Isolation.  Embryos are 
created by IVF, and grown to the blastocyst stage (diagram left).  A 
micropipette is used to extract ES cells from the inner cell mass, and they 
are grown in co-culture with human or mouse cells which provide a 
scaffold and growth factors (diagram center).  (How Embryonic, 2010) 
 
Parthenote ES Cells 
Another type of ES cell is a Parthenogenetic ES cell.  Parthenogenesis in nature is a type 
of asexual reproduction common in bees and ants, but it does not normally occur in mammals.  
In the lab, eggs are chemically treated with strontium chloride to induce cell division without 
fertilization.  The eggs divide to form blastocysts from which ES cells can be obtained (Linzhao, 
2008).  An interesting fact about mammalian parthenote embryos is that they do not divide 
beyond the blastocyst stage, so they cannot form fetuses. Some scientists believe parthenote 
embryos might serve as an alternative source of ES cells since their inability to form fetuses 
reduces some ethical concerns. 
Figure-3 shows the formation of a parthenote.  During normal reproduction (left side), 
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each egg initially begins with 2 complete sets of chromosomes (Howard, 2007), but during 
oogenesis (egg formation) half the number of chromosomes is lost.  After fertilization with a 
sperm that contains a haploid number of chromosomes, the normal diploid number of 
chromosomes is reestablished in the embryo.  During parthenogenesis (diagram right side), an 
egg is treated with strontium chloride to prevent expulsion of any chromosomes and to induce 
cell division.  The embryo divides to the blastocyst stage from which ES cells are obtained.  
When a blastocyst is grown using parthenogenesis, it cannot grow into a full organism, but it can 
provide a source of ES cells that will be an exact genetic match to the oocyte (egg) donor, and 
will also be histocompatible with a small percentage of the rest of the population (Linzhao, 
2008).  Parthenote ES cells have been obtained from monkeys (Cibelli et al., 2002) and mice 
(Genetically Matched, 2006), but have not yet been obtained in humans. 
 
Figure-3:  Diagram of Parthenogenesis.  
During normal reproduction (left side), half 
the complement of X chromosomes is 
eliminated from the egg prior to fusion with 
the sperm where it picks up the other half of 
the chromosome complement to form a 
normal diploid embryo.  During 
parthenogenesis (diagram right), the egg is 
chemically treated to prevent loss of half the 
chromosomes and to induce cell division.  No 
fusion with sperm occurs, and the embryo 
grows to the blastocyst stage from which ES 
cells are obtained.  (Howard, 2007) 
 
iPS Cells 
Another potential source of ES cells are induced pluripotent (iPS) cells .  Due to the 
controversial nature of using IVF embyos, scientists are always searching for alternative sources 
of ES cells.  In 2007, a glimmer of hope shone through the turmoil when two research groups, 
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one led by James Thompson at the University of Wisconsin (Yu et al., 2007), and the other by 
Yamanaka in Japan (Takahashi et al., 2007), discovered a process by which adult cells can be 
returned to their pluripotent state by means of genetic alteration through viral integration of 
transcription factors (NB, 2008).  Initially the process involved using a virus to integrate four 
transcription factor genes, including an oncogene, into adult skin fibroblast cells to genetically 
alter them to regress (Novel Strategy, 2010).  Because these cells sometimes formed tumors 
when injected into mice, subsequent experiments omitted the oncogene, and were still able to 
obtain iPS cells (Nakagawa et al., 2008).  These cells do not form tumors upon injection into 
mice (Novel Strategy, 2010).  Although some reports show that iPS cells appear to be 
pluripotent, other reports indicate the cells are harder to grow than ES cells (Vogel, 2010). 
If these iPS cells prove to be pluripotent and can one day be transplanted safely into 
human patients, the two biggest issues surrounding stem cell research will be solved.  With the 
use of iPS cells doctors and scientists will eventually be able to take a skin biopsy from any 
patient and make iPS cells to specifically treat their illness—and since the original cells came 
from the patient, there will be no risk of immune rejection once the transplant is complete (NB, 
2008). 
 
Adult Stem Cells 
Adult stem cells (ASCs) are the most uncontroversial type of stem cell.  ASCs are found 
inside different adult tissues, and are specific to those sites.  These cells play a critical role in 
tissue maintenance and repair (Stem Cell Basics, 2010).  Research on adult stem cells began in 
the 1950s with the discovery of multipotent hematopoietic and mesenchymal stem cells in bone 
marrow, which can generate a number of tissues from lymphocytes and basophils, to fat and 
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cartilage (Stem Cell Basics, 2010). Now scientists have been able to find ASCs in a plethora of 
adult tissues that can be used for a number of treatments including the repair of damaged heart 
muscle, and transplanting insulin-producing cells for individuals with type I diabetes (Stem Cell 
Basics, 2010). 
ASCs are far more difficult to isolate than ES cells, and are difficult to grow.  ASCs can 
sometimes be identified in the body with the use of molecular markers on their cell surface, but 
because their division is limited, so researchers have been trying to find a more efficient way to 
grow them (Stem Cell Basics, 2010).  An interesting method has been found at Stanford 
University regarding the growth of adult muscle stem cells.  When the cells are in the body they 
sit on the soft tissue and rub against other cells and tissues—researchers have been able to create 
a softer culture medium that influences the cells to act as if they were in their home environment 
(Scientists Develop New Way, 2010).  The problem in the past has been that ASCs grown on 
standard culture plates are likely to stop dividing, so it is hard to obtain enough cells to be 
medicinally useful.  With the use of this new, more elastic growth medium, more cells have been 
preserved after division and the new cells are less likely to differentiate before transplantation 
(Scientists Develop New Way, 2010).  Researchers at Stanford University transplanted ASCs 
grown on the new medium  into 24 mice with muscle degeneration—12 with the “old cells” and 
12 with the “new cells”, and the results showed that ¼ of the mice with the new cultured cells 
responded to the treatment, while none that received the old cultured cells did.  Though this new 
culture method has only been tested for muscle cells, these same researchers believe that it will 
work for all types of stem cells (Scientists Develop New Way, 2010). 
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Chapter-2: Stem Cell Applications 
Harry Hovagimian 
 
Now that we have discussed in the previous chapter the various types of stem cells, we 
now turn our attention to what stem cells have been used for.  The purpose of this chapter is to 
discuss stem cell applications and their benefits to society, to facilitate our subsequent discussion 
of stem cell ethics where the benefits versus detriments are balanced. 
Stem cells have many applications, each in various stages of development, from the 
discovery stage, to mammalian testing, and even human trials.  The legalities (which we will 
speak about later in Chapter 4) are stricter for human testing, but in most cases animal testing 
must be done prior to testing in humans, so in some cases only animal data is available at this 
time.  Having some applications still in the animal testing stage does not minimize the weight of 
the data, as this is a required step before proceeding to human testing, but obviously obtaining 
human data is the desired goal.  Animal testing is not a perfect predictor of success in humans, 
but it has been mostly accurate in the past in a variety of tests, ranging from testing how fish oil 
supplements affect breast cancer in rats (Su, Hsieh, & Chen, 2010), to xenotransplantation of 
genetically engineered pigs‟ organs (Ekser, Rigotti, Gridelli, & Cooper, 2009).  Some stem cell 
treatments are currently being tested in humans, but early clinical experiments usually use 
patients with poor prognosis who did not respond to conventional therapies, so this can bias 
against success (Steen & Medsger, 2000).  This chapter will focus on applications of stem cell 
treatments for five different diseases. Each section will introduce a disease, explain how it is 
being treated presently and in the recent past, and explain how the stem cell treatment is 
changing or will soon change the patient prognosis. 
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Stem Cell Treatment of Diabetes 
Diabetes is a chronic disease that affects a patient‟s blood sugar levels. It is currently the 
sixth leading cause of death in the United States (Goldthwaite, 2008). The two most common 
types, type 1 and type 2, are symptomatically similar in that the patient‟s blood glucose levels are 
high, but this is where any similarities end.  Type-1 diabetes is an autoimmune deficiency in 
which the body attacks the pancreas, where insulin is made. This results in the patient not having 
enough insulin to properly control blood sugar levels. Type-2 diabetes transpires when the 
insulin the body creates is not efficient enough for removing the sugar from the blood. In this 
case, the pancreas produces insulin, but the tissues have decreased their response to it.  The 
treatment for type-2 typically involves controlling weight and diet, and increasing physical 
activity.  The current treatment for type-1 is usually limited to monitoring the patient‟s blood 
sugar levels closely and controlling it with insulin injections.  While the economic cost of 
diabetes is in the hundreds of billions annually in the US, we still can only treat the symptoms of 
the disease (Goldthwaite, 2008). 
Stem cells have the capacity to create the insulin-producing β cells, which are necessary 
to treat type-1 diabetes.  The pancreas is the organ that monitors and controls the levels of 
insulin, and therefore glucose, in the blood stream. The study of pancreatic regeneration is 
strongly under investigation, but by generating new islet cells, we could possibly treat this 
disease  (Goldthwaite, 2008). 
Another organ being investigated as a source for islet producing stem cells is the spleen. 
The spleen has regained research attention after the discovery of the multipotent stem cells 
within this organ that are strongly capable of self-renewal and injury repair, including producing 
insulin manufacturing cells.  These cells, when successfully harvested, have been shown to 
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secrete insulin, while being less likely to form cancerous tumors unlike embryoinc stem (ES) 
cells  (Faustman & Davis, 2010). 
With respect to ES cell treatments of diabetes, although ethical and legal disputes control 
the use of these cells, experiments have shown that human ES cells are capable of being 
differentiated in vitro into insulin producing cells (Assady et al., 2001), and that ES cells can be 
used to treat animal models for type-1 diabetes (Soria et al., 2000).  This latter study corrected 
hyperglycemia in nonobese diabetic (NOD) mice within one week (Soria, Roche, Berná, León-
Quinto, Reig, & Martín, 2000).  The Assady study showed that human ES cells had greater 
potential to create cells with insulin-producing capacity than mouse ES cells (Assady, Maor, 
Amit, Itskovitz-Eldor, Skorecki, & Tzukerman, 2001).  Human ES cells have not yet been used 
to treat type-1 patients, so this remains a future possibility. 
One interesting study showed that the transplantation of MHC-matched hematopoietic 
stem cells (HSCs) in diabetic NOD mice led to successful blocking of disease formation, so 
perhaps these adult stem cells can be used in patients in the near future (Beilhack et al., 2003; 
2005). 
 
Stem Cells and Systemic Sclerosis 
Systemic sclerosis (also known as scleroderma, diffuse scleroderma or SSc) is an 
autoimmune disease which can manifest in different forms. „Sclero‟ is the Anglo version of the 
Greek word sklero meaning hard (MedicineNet, 2004), and derma is the Greek word for skin 
(MedicineNet, 2004). While literally translated scleroderma means hardening of the skin, other 
organs are often affected, including the lungs, heart, kidneys, and gastrointestinal tract. This 
systemic involvement is frequently associated with an ultimately fatal prognosis, while localized 
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sclerosis primarily affects the patient‟s skin and has not been shown to impact the patient‟s 
mortality (Hunzelmann & Krieg, 2010) (International Scleroderma Network (ISN), 1998-2010). 
Like other autoimmune diseases, SSc develops when a person‟s immune system malfunctions in 
response to an unknown trigger and the immune system attacks itself.  SSc patients are 
categorized by the extent of skin involvement, though, as previously stated, other organs are 
typically affected. 
Current treatments for SSc often target the organ fibrosis. Current treatments include 
general immunosuppression, corticosteroid treatments, anti-fibrotic therapies, and a wide array 
of anti-inflammatory drugs, though there is no clear proof that any other these methods treat the 
underlying disease (Hunzelmann & Krieg, 2010) (Mouthon, Bérezné, Guillevin, & Valerye, 
2010). 
One current use of stem cells for this disease is to treat finger joint deformity (known as 
clawing) in patients with diffuse scleroderma. A study was done to assess the effects of 
autologous hematopoietic stem cell transplantation (ASCT) on scleroderma finger clawing, and 
promising results were shown on both structural and functional levels for the patients‟ hands. 
Prior to ASCT, the patients‟ Rodnan skin scores for the hands ranged from 6-12 out of 12 (the 
lower the better).  Following ASCT, the scores ranged from 0-6. The modified Rodnan skin 
score (MRSS) is an assessment of the thickness of the patients‟ skin in various types of SSc 
(Englert, et al., 2008). 
Hematopoietic stem cell treatments have also been shown to reverse capillary bed 
damage and loss in scleroderma patients who had undergone immunosuppressive therapy 
followed by autologous HSC transplantation. The capillaries in the dermis of these patients not 
only benefitted from capillary regeneration, resulting in reduced pain and increased mobility, but 
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it affected capillary beds in other organs, reducing the risk for heart failure, hypertension, and 
pulmonary fibrosis for example, which ultimately increased the patient‟s expected life span 
(Fleming, et al., 2008). 
Another treatment still in development focuses on the disease‟s autoimmune defects. 
Most current treatments use chemotherapy to destroy the patient‟s immune system, followed by 
various anti-inflammatory drug treatments.  Some new treatments use radiation and 
chemotherapy to destroy affected bone marrow, followed by ASCT to create a new immune 
system in the patient‟s bone marrow (Hunzelmann & Krieg, 2010).  This high-dose 
chemotherapy and radiation followed by ASCT is not limited to treating SSc, it is also being 
researched for lupus, rheumatoid arthritis, and other autoimmune diseases (Green, 2006) (Fisher, 
2006). 
 
Stem Cell Treatment of Stroke 
A stroke, sometimes called a cerebrovascular accident (CVA), is caused when the blood 
supply to the brain is rapidly decreased, resulting in rapid loss of function. There are two types of 
stroke, ischemic and hemorrhagic, in which blood flow is decreased due to a blockage or the 
leakage of blood, respectively. Stroke is the third leading cause of death in developed countries, 
with ischemic stroke accounting for more than 80% of all strokes (National Stroke Association, 
2009) (Sims & Muyderman, 2010).  There are a number of risk factors for strokes, ranging from 
age, behavior, health, and previous stroke. Current treatment varies, but typically includes 
thrombolysis, breaking down the clot, or physically removing the clot via a thrombectomy. Time 
is the limiting factor with a stroke, as brain cells will continue to die without sufficient blood 
flow and ultimately lead to death if untreated.  During a stroke, brain cells die, and the abilities 
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controlled by that area of the brain are lost.  This can include physical abilities such as speech 
and muscle movement, or loss of memory, depending on the location damaged, the extent of 
damage, and the duration before the thrombus is removed. 
With respect to animal studies, mesenchymal stem cell (MSC) therapy has shown 
improvements in behavioral and neurological recovery from ischemic stroke in rats. Tests have 
shown improved recovery in rats treated with MSCs isolated from the rat‟s own bone marrow, 
although the optimal timing and dosage still need to be investigated further (Pavlichenko, et al., 
2008). To find these critical answers, two federally funded studies investigated how many cells 
should a dose consist of, and when is the optimal time to administer such doses (Medical College 
of Georgia, 2008).  Drs. Hess, Yu, Borlongan, and other investigators are neuroscientists at the 
Medical College of Georgia and have worked on many types of cells in the transplantation 
therapy in ischemic stroke rat model. 
MSCs are not the only type of stem cells to be successfully transplanted into ischemic 
rats.  Human fetal NSCs have been shown to survive, migrate, and differentiate in the brains of 
ischemic rats, and further testing will reveal if these new neural cells affect the recovery of motor 
function. These NSCs are known to survive in non-obese diabetic (NOD) mice, a study discussed 
earlier in treating diabetes.  The survival of the ischemic rats significantly increased 3.8% over a 
four week post-transplant time period.  As a comparison, a 3.8% increase of a human‟s average 
life span of 70.2 years (CIA, 2010) would be roughly two years and eight months (Kelly, et al., 
2004). 
Some data is also available for human stroke patients.  Dr. Rich James, a chiropractor and 
resident of New York City, suffered a massive stroke in February 2006. Through the internet, he 
contacted Stem Cell Therapy International, Inc, a company located in Florida devoted to the 
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development of stem cell transplantation therapy for regenerative medicine.  James, who suffered 
crippling effects to his left side, underwent stem cell therapy with an affiliate clinic overseas in 
Kiev, Ukraine (Vega, 2006).  Within six weeks, he was back home in Manhattan, able to ride the 
NYC subway on his own, a feat that was previously difficult with his quad cane and brace or his 
wheelchair.  Although this report shows promising data, it does not represent a well-controlled 
clinical trial, so a proper study remains in the future (Vega, 2006). 
 
Stem Cell Treatment of Alzheimer’s Disease 
Alzheimer‟s disease (AD) is a neurodegenerative brain disorder, and it accounts for 
approximately two-thirds of all cases of dementia.  Named for the German physician who first 
described the disease at the turn of the 19
th
 century, Alzheimer‟s is the most common form of 
dementia in people over the age of 65.   It is currently incurable, largely because its causes are 
not fully understood.  Presently, treatments for AD offer patients temporary symptomatic relief, 
but do not delay the disease‟s progression. While most AD cases occur in patients over the age of 
65, early-onset AD can occur in patients as early as 40 years old.  The average mortality for AD 
is five years, but this can range from three to twenty years.  AD patients require a dedicated 
caregiver, and two-thirds of those patients living in the United States are taken care of by a 
family member or friend in their own home. This disease is not only taxing emotionally on the 
patient‟s family, but the annual cost to family members is typically in the thousands of dollars up 
to $100,000 (Bloom, de Pouvourville, & Straus, 2003) 
Current AD research shows that amyloid-β (Aβ), a short neurotoxic polypeptide chain, is 
likely associated with neurodegenerative diseases such as Alzheimer‟s. The deposition and build 
up of these small protein fragments into senile plaques was observed as far back as Auguste 
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Deter, the first AD patient studied by Alois Alzheimer in 1906.  Reducing the production and 
buildup of these peptides may be part of treating this disease.  Although Aβ is thought to initiate 
the disease, tau protein participates in the downstream effects.  Tau is a protein normally 
associated with microtubules inside a cell that help maintain cell shape.  In AD patients, tau 
becomes hyper-phosphorylated, which ruins microtubule formation and cell shape, forming 
neurofibillary tangles (Alzheimer's Association, 2010). 
With respect to potential stem cell treatments, researchers at the Kyungpook National 
University in Daegu, South Korea, tested the potential therapeutic effects of bone marrow-
derived MSCs in mice. The 2009 study was able to successfully confirm that BM-MSC 
transplantation accelerated the removal of amyloid-β plaques from the brains of acute AD mice 
(Lee et al., 2009). This study also showed that the BM-MSCs can induce normally-quiescent 
microglia to clear out amyloid-β build-up (Lee, Jin, & Bae, 2009).  The three professors who 
performed the 2009 study in Korea reported in early 2010 that the decreased amyloid-β 
deposition was directly related to microglial activation (Lee et al., 2010).  They also showed that 
the microglia ameliorate memory deficiencies in the AD mice. This finding was supported by a 
version of the Morris water maze test known as the hidden platform. Subjects which received 
PBS injections deteriorated as expected in their ability to learn and memorize the maze, while 
those treated with BM-MSCs displayed navigational patterns that resembled control subjects.  
Furthermore, they reported that the MB-MSC transplantation was able to reduce tau 
hyperphosphorylation (Lee, Jin, Endo, Schuchman, Carter, & Bae, 2010). 
Another type of stem cell being investigated as a possible AD treatment is adult neural 
stem cells (NSCs).  Recent advances in isolation techniques for NSCs have made NSCs exciting 
candidates for a variety of therapeutic strategies, including the treatment of AD.  NSCs are 
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multipotent cells that generate various cells in the central nervous system (CNS).  Research using 
NSCs will determine their ability to reduce tau hyperphosphorylation and amyloid-β deposition. 
Surprisingly, at this time there appears to be no discussion about using NSCs to generate 
activated microglia. 
 
Stem Cell Treatment of Lung Carcinoma 
Carcinoma of the lung, or lung cancer, is typically classified within two main types. The 
most common type is non-small cell lung carcinoma (NSCLC) which comprises approximately 
80% of all cases.  Small cell lung carcinoma (or SCLC) constitutes the remaining cases. At the 
time of diagnosis, SCLC is typically widespread in the patient‟s body, so treatment is usually 
limited to radiation and/or chemotherapy.  With NSCLC, the cancer may remain centralized, 
allowing for surgical removal of the tumor (Healthcommunities.com, Inc., 2007). 
Presently, SCLC is typically treated with radio-chemotherapy, since there is no 
centralized tumor for resection. This is where stem cells come into the picture as a possible 
treatment.  A group at the University of Berne in Switzerland treated patients with limited-
disease SCLC with intensive chemotherapy, supported by stem cell-enriched whole blood and 
radiotherapy.  Although they have not obtained enough results to determine whether this is a 
significantly improved treatment method, they were able to determine that the treatment was less 
toxic than standard treatments with ifosfamide, carboplatin and etoposide.  SCLC patients may 
even have a good survival benefit with this treatment (Calderoni, von Briel, Aebi, Solenthaler, & 
Betticher, 2002).  Further reporting on this study could not be located at the time of writing this 
project. 
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Other possible uses of stem cells for treating lung cancer have shown interesting results. 
In 2006, a group from the JG Brown Cancer Center at the University of Louisville presented 
their findings regarding ES cells used as a treatment for lung cancer in mice (Eaton et al., 2006). 
Mice were given two possible treatments, then tumors were implanted.  Treatment with ES cells 
alone proved 80% effective in preventing tumor growth, while using ES cells plus granulocyte-
macrophage colony-stimulating factor (GM-CSF) prevented 100% of tumor growth. The work 
done by Professor Eaton and his colleagues at the Center was funded mostly by small local 
grants, with larger federal agencies remaining disinterested in funding and supporting such work 
(Eaton, et al., 2006). 
A Japanese study was presented in the journal Lung Cancer in mid-2003.  It was 
designed to show the survival of patients who had first undergone radiation and chemotherapy 
treatments with high-dose ifosfamide, carboplatin and etoposide (HD-ICE), supplemented with 
peripheral blood stem cell transplantation (PBSCT) for SCLC  (Katakami, et al., 2003).  This 
study showed promising results in 5-year survival rates.  Based on the excellent data from the 
first study, a further investigation, a comparative phase III study of radio-chemotherapy and 
radio-chemotherapy followed by HD-ICE with PBSCT, is currently was underway at the time of 
this IQP. 
Another study tested HD-ICE (defined above) with autologous PBSCT in a phase II trial 
conducted with patients who had not previously undergone any treatment for their LD-SCLC 
(Nakanishi et al., 2003). The phase II trial seems to have started concurrently with the previously 
discussed study, and showed an overall survival rate at around 50 to 55.6% ± 11.7%.  The results 
show that HD-ICE combined with auto-PBSCT is a viable treatment option.  This data, 
combined with the data from the previously mentioned trial, show that a treatment involving 
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HD-ICE combined with PBSCT is a viable treatment option for patients with small cell lung 
carcinoma. 
 
Chapter-2 Works Cited 
 
Alzheimer's Association. (2010, August 5). What is Alzheimer's. Retrieved August 6, 2010, from 
alz.org - Alzheimer's Association: 
http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp 
 
Assady, S., Maor, G., Amit, M., Itskovitz-Eldor, J., Skorecki, K. L., & Tzukerman, M. (2001). 
Insulin Production by Human Embryonic Stem Cells. Diabetes , 50, 1691-1697. 
 
Beilhack, G. F., Landa, R. R., Masek, M. A., & Shizuru, J. A. (2005). Prevention of type 1 
diabetes with major histocompatibility complexcompatible and nonmarrow ablative 
hematopoietic stem. Diabetes  54, 1770-1779. 
 
Beilhack, G. F., Scheffold, Y. C., Weissman, I. L., Taylor, C., Jerabek, L., Burge, M. J., et al. 
(2003). Purified Allogeneic Hematopoietic Stem Cell Transplantation Blocks Diabetes 
Pathogenesis in NOD Mice. Diabetes , 52, 59-68. 
 
Bloom, B. S., de Pouvourville, N., & Straus, W. L. (2003). Cost of Illness of Alzheimer‟s 
Disease: How Useful Are Current Estimates? The Gerontologist , 43 (2), 158-164. 
 
Calderoni, A., von Briel, C., Aebi, S., Solenthaler, M., & Betticher, D. C. (2002). Intensive 
chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small 
cell lung cancer: a phase I/II trial. Lung Cancer , 36 (3), 321-326. 
 
CIA. (2010). CIA - The World Factbook -- Country Comparison :: Life expectancy at birth. 
Retrieved July 30, 2010, from CIA.gov: https://www.cia.gov/library/publications/the-world-
factbook/rankorder/2102rank.html 
 
Eaton, J., Mitchell, R., Brewer, B., Krishnan, E., Williams, L., Gao, X., et al. (2006). Embryonic 
stem cell vaccination prevents lung cancer. European Journal of Cancer Supplements , 4 (12), 
13. 
 
Ekser, B., Rigotti, P., Gridelli, B., & Cooper, D. K. (2009). Xenotransplantation of solid organs 
in the pig-to-primate model. Transplant Immunology , 21, 87-92. 
 
Englert, H., Kirkham, S., Moore, J., Poon, T. S., Katelaris, C., McGill, N., et al. (2008). 
Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and 
function. Internal Medicine Journal (38), 692-696. 
 
 25 
Evans, M., & Kaufman, M. (1981). Establishment in culture of pluripotential cells from mouse 
embryos. Nature , 154-156. 
 
Faustman, D. L., & Davis, M. (2010). Stem cells in the spleen: Theraputic potential for Sjogren's 
syndrome, type 1 diabetes, and other disorders. The International Journal of Biochemistry & Cell 
Biology , 4. 
 
Fisher, J. P. (2006, July 20). Study puts hope in stem cells: Duke researchers target scleroderma. 
News & Observer . 
 
Fleming, J. N., Nash, R. A., McLeod, D. O., Fiorentino, D. F., Shulman, H. M., Connolly, M. K., 
et al. (2008). Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? 
PLoS ONE , 3 (1). 
 
Goldthwaite, C. A. (2008, May). Are Stem Cells the Next Frontier for Diabetes Treatment? 
Retrieved June 20, 2010, from Stem Cell Information: 
http://stemcells.nih.gov/info/2006report/2006Chapter7.htm 
 
Green, S. D. (2006, December 14). New treatment gives hope to patients with scleroderma; 
STEM CELLS PLAY PART IN BATTLE. The Houston Chronicle , 2. 
 
Healthcommunities.com, Inc. (2007, December 04). Types of Lung Cancer - Lung Cancer - 
Oncology Channel. (S. J. Swierzewski, Editor) Retrieved July 20, 2010, from 
HealthCommunities.com: http://www.oncologychannel.com/lungcancer/types.shtml 
 
Hunzelmann, N., & Krieg, T. (2010). Scleroderma: from pathophysiology to novel. Experimental 
Dermatology (19), 393-400. 
 
International Scleroderma Network (ISN). (1998-2010). Systemic Sclerosis (Scleroderma): 
Prognosis and Mortality. Retrieved June 18, 2010, from Sclero.org: 
http://sclero.org/medical/about-sd/types/systemic/prognosis/a-to-z.html 
 
Internet Broadcasting Systems, Inc. (2005, June 1). After Mass. Enacts Stem Cell Law, Conn. 
Moves Ahead - Health News Story - WCVB Boston. Retrieved July 30, 2010, from WCVB TV5 
Boston: http://www.thebostonchannel.com/health/4554491/detail.html 
 
Katakami, N., Kinose, D., Ikeda, A., Yoshioka, H., Hayashi, M., Nishimura, T., et al. (2003). P-
57 High-dose ifosfamide, carboplatin and etoposide (HD-ICE) with peripheral blood stem cell 
transfusion (PBSCT) for limited stage small-cell lung cancer (LD-SCLC). Lung Cancer , 41 
(Supplement 2), S105. 
 
Kelly, S., Bliss, T. M., Shah, A. K., Sun, G. H., Ma, M., Foo, W. C., et al. (2004). Transplanted 
human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. 
PNAS , 101 (32), 11839-11844. 
 
 26 
Lee, J. K., Jin, H. K., & Bae, J.-s. (2009). Bone marrow-derived mesenchymal stem cells reduce 
brain amyloid-β deposition and accelerate the activation of microglia in an acutely induced 
Alzheimer‟s disease mouse model. Neuroscience Letters , 450, 136-141. 
 
Lee, J. K., Jin, H. K., Endo, S., Schuchman, E. H., Carter, J. E., & Bae, J.-s. (2010). Intracerebral 
Transplantation of Bone Marrow-Derived Mesenchymal Stem Cells Reduces Amyloid-Beta 
Deposition and Rescues Memory Deficits in Alzheimer‟s Disease Mice by Modulation of 
Immune Responses. Stem Cells , 28, 329-343. 
 
Medical College of Georgia. (2008, January 30). Stem Cell Therapy Studies For Stroke, Cerebral 
Palsy Prepare For Clinical Trials. Retrieved June 28, 2010, from Science Daily: 
http://www.sciencedaily.com/releases/2008/01/080129160714.htm 
 
MedicineNet. (2004, November 4). Derma- difinition - Medical Dictionary. Retrieved June 20, 
2010, from MedicineNet.org: http://www.medterms.com/script/main/art.asp?articlekey=40313 
 
MedicineNet. (2004, September 15). Sclero- definition - Medical Dictionary. Retrieved June 20, 
2010, from MedicineNet.com: http://www.medterms.com/script/main/art.asp?articlekey=13531 
 
Mouthon, L., Bérezné, A., Guillevin, L., & Valerye, D. (2010). Therapeutic options for systemic 
sclerosis related interstitial lung diseases. Respiratory Medicine (104), S59-S69. 
 
Nakanishi, Y., Kiura, K., Ueoka, H., Yamaguchi, K., Kasahara, K., Arita, K., et al. (2003). P-60 
Phase II study of high-dose ifosfamide, carboplatin and etoposide with autologous peripheral 
blood stem cell transplantation for limited-disease small-cell lung cancer. Lung Cancer , 41 
(Supplement 2), S106. 
 
National Stroke Association. (2009). National Stroke Association: What is Stroke. Retrieved 
June 28, 2010, from Stroke.org: http://www.stroke.org/site/PageServer?pagename=STROKE 
 
Pavlichenko, N., Sokolova, I., Vijde, S., Shvedova, E., Alexandrov, G., Krouglyakov, P., et al. 
(2008). Mesenchymal stem cells transplantation could be beneficial for treatment of 
experimental ischemic stroke in rats. Brain Research , 1233, 203-213. 
 
Roche, E., Sepulcre, M. P., Ensenat-Waser, R., Maestre, I., Reig, J. A., & Soria, B. (2003). Bio-
engineering insulin-secreting cells from embryonic stem cells: a review of progress. Medical & 
Biological Engineering & Computing , 41 (4), 384-391. 
 
Sims, N. R., & Muyderman, H. (2010). Mitochondria, oxidative metabolism and cell death on 
stroke. Biochimica et Biophysica Acta, 1802, 80-91. 
 
Soria, B., Roche, E., Berná, G., León-Quinto, T., Reig, J. A., & Martín, F. (2000). Insulin-
Secreting Cells Derived From Embryonic Stem Cells Normalize Glycemia in Streptozotocin-
Induced Diabetic Mice. Diabetes , 49, 157-162. 
 
 27 
Steen, V. D., & Medsger, J. T. (2000). Severe Organ Involement in Systemic Sclerosis with 
Diffuse Scleroderma. Arthritis & Rheumatism , 43 (11), 2437-2444. 
 
Su, H.-M., Hsieh, P.-H., & Chen, H.-F. (2010). A maternal high n-6 fat diet with fish oil 
supplementation during pregnancy and lactation in rats decreases breast cancer risk in the female 
offspring. Journal of Nutritional Biochemistry , 1033-1037. 
 
Vega, J. (2006, November 30). Stem Cell Treatment Successful for Stroke Survivor. Retrieved 
July 12, 2010, from About.com: http://stroke.about.com/b/2006/11/30/stem-cell-treatment-
successful-for-stroke-survivor.htm 
 28 
Chapter-3: Stem Cell Ethics 
Sarah Nuccitelli 
 
The use of embryonic stem cells as medical treatments sometimes involves the 
destruction of embryos that hold the potential to grow into a complete human organism, so it is 
important to consider the ethics behind this science—religious groups and people around the 
world have many different opinions as to how society should proceed with stem cell research.  In 
this chapter, we will investigate the views of the world‟s five major religions on stem cells: 
Judaism, Christianity, Hinduism, Islam, and Buddhism.  The purpose of this chapter is to explore 
different ethical stances of world religions to provide an understanding as to the morality of stem 
cell research.  Surprisingly, all of these religions support the research and use of adult stem cells 
(ASCs) as long as they are used to save lives (Griffin, 2010). 
 
The Stem Cell Debate 
The stem cell debate is mainly centered around embryonic stem (ES) cells and the 
controversy of when human life begins.  Some believe that life begins as early as conception, 
while others believe life begins much later at birth (Yearwood, 2001).  When life begins is an 
important factor in determining whether the harvesting of ES cells kills human beings.  
Individuals opposed to ES stem cell research believe that the blastocyst (from which ES cells are 
derived) should be considered with the same respect as a fully developed human, and they 
compare the killing of the blastocyst to murder (Doerflinger, 1999).  Thus, in our discussion of 
each religion below, we will focus on their beliefs of when life begins. 
In addition to when life begins, several other arguments also contribute to the opposition 
of ES cell research.  Somatic cell nuclear transfer (SCNT), or therapeutic cloning, is a process 
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that involves removing the nucleus from an unfertilized egg, and replacing it with the nucleus 
from an adult cell.  The reconstituted egg is then stimulated to divide for 5 days to the blastocyst 
stage from which ES cells can be derived (Somatic Cell Nuclear Transfer, 2003).  The advantage 
of SCNT is that ES cell lines could be created from a specific patient to be used for treating that 
same patient without fear of graft rejection.  But so far SCNT has successfully been performed in 
mice, not in humans.  Though SCNT offers a way to obtain many ES cell lines, the manipulation 
of embryos solely for science (not reproduction) is considered by some to be unethical because 
these embryos are being created merely to be destroyed (Committee on Ethical Guidelines et al., 
2005).  Other ethical concerns also surround using a technique that mixes human and nonhuman 
cells.  Scientists sometimes grow ES cells on animal cell feeder layers, which can increase the 
risk of viral transmission to the human cells.  In addition, sometimes human ES cells are 
transplanted into nonhuman animals to create chimeras (hybrids), so that the human cells can be 
studied for applications (Karpowicz et al., 2004).  Chimeras, whose name is derived from the 
Greek word for an interspecies mythical beast, raises concerns for some religious groups because 
some historical influences suggest that creating these hybrids is evil (Karpowicz et al., 2004).   
ES cells hold more medical potential than adult stem cells (ASCs) because they are easier 
to grow in large quantities, are easier to isolate, and can differentiate into a larger variety of 
tissues.  Because ES cells hold so much medical potential, a new kind of ES cell is being studied 
that does not destroy an embryo.  Induced pluripotent stem (iPS) cells are regular skin fibroblast 
cells that have been reprogrammed back to their pluripotent state by transfection with DNAs 
encoding stem-inducing transcription factors.  This process allows the fibroblast cells to develop 
into ES-like cells (Brind'Amour, 2009).  As discussed in Chapter-1, iPS cells are very promising 
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because some scientists believe they have the same abilities as ES cells, however other scientists 
believe iPS cells divide slower and are less robust (Dolgin, 2010). 
 
Christianity and Stem Cells 
Christianity is the world‟s largest religion, divided into nearly 400 million Protestants, 
and over 1 billion Catholics (Griffin, 2010).  As is typical for the very large religions, multiple 
stances exist within one religion.  Some followers of Christianity, especially Catholics, oppose 
the use of ES cells as they believe life begins at conception, thus an embryo is a form of human 
life, and its destruction constitutes murder, a sin in the eyes of god (Doerflinger, 1999).  Before 
there was advanced biological knowledge about human embryonic life, followers of Christianity 
believed that the embryo only attained human status when it took a general human shape; but in 
1869 Pope Pius IX declared the fetus to have full human status (Fazzetto, 2004).  In a direct 
quote from Pope John Paul II, he stated that “In reality from the moment in which the ovum is 
fertilized, a new life begins which is not that of the father or of the mother but of a new human 
being which develops of its own accord. It would never be made human if it were not human 
already.  This has always been clear, and modern genetic science offers clear confirmation” 
(Robinson, 2006).  The Pope is an idyllic figure to most Catholics, and his beliefs and opinions 
represent the general views of the Catholic church.  At a 1996 U.S Bishop's conference, concern 
was expressed that any approval from the Catholic Church on ES cell research would encourage 
further degradation of humanity for the purposes of scientific advancement (O'Brien, 1996).  
This means that if religious role models supported the use of ES cells, it would increase the 
exploitation of blastocysts, whether they are from IVF clinics or grown in vitro.  The pro-life 
document presented by the 1996 Bishops committee disputes stem cell research on the grounds 
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that medical potential and hope for the greater good does not justify direct killing (O'Brien, 
1996).   They believe that embryos deserve the same respect as all other human beings based on 
the fact that the fertilized egg contains all of the genetic material needed to become a human 
being—which can lead to the conclusion that there is no real difference between an embryo and a 
full grown person (Robinson, 2006).  With such a strong stance against ES research, it is not 
surprising that Catholicism also does not support the use of discarded embryos for research.  In 
respect to IVF clinics, it was stated that “ultimately each of us will die, but that gives no one the 
right to kills us” (O'Brien, 1996).  Although Catholics are strongly against embryo research, the 
Pope has been quoted as being in favor of working with adult stem cells (Pope Benedict XVI, 
2008). 
While Catholics have tight restrictions against embryo research, other Christians such as 
Methodists and Episcopalians, approve of it (Faithful Profressive, 2005).  Such research is 
supported as “ethically responsible advances” (O'Brien, 1996).  This support for some types of 
research show that large religions are often divided, and some Christians understand the 
importance and potential that stem cells hold. 
 
Judaism 
Judaism is the oldest major religion, with approximately 18 million followers—one third 
of which live in the United States (Griffin, 2010).  The Jewish community is divided, and there 
exists no official singular stance on the subject of stem cell research (Yearwood, 2001). 
However, Jewish faith requires its members to seek scientific knowledge, and most see fit to 
pursue ways to improve human life (Fazzetto, 2004).  For this reason, a large portion of Jewish 
members feel that "Pikuach nefesh" or the "Preservation of life" can be best served using stem 
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cells for the betterment of existing and ailing humans; however others believe that the destroying 
embryos by dissecting their stem cells goes against the idea of improving humanity (Yearwood, 
2001).  With over 100,000 frozen embryos in IVF clinics, most members of Judaism are at least 
in favor of researchers trying to use them to save lives (Yearwood, 2001).  Jewish tradition 
permits the destruction of an embryo for the benefit of other living human beings because Jewish 
law declares that life begins at birth not at conception (Rich, 1997).  In addition, the destruction 
an embryo is especially allowed if it is only grown outside the body because that embryo has no 
chance to develop, so it is ethically of lower status than an implanted embryo (Yearwood, 2001).  
This Jewish acceptance of an in vitro state also allows for therapeutic cloning, as that embryo 
would also grown only outside the body (Fazzetto, 2004). 
 
Islam 
Islam is the world‟s second largest religion to Christianity, whose followers (Muslims) 
believe in the Prophet Muhammed, who was sent from God (Allah) to guide them—mortal life is 
believed to be a preparation for the after-life (Griffin, 2010).  There exists no solid Islamic stance 
on ES cell research, but it is common Muslim belief that it takes the embryo 120 days (4 months) 
after fertilization to obtain a soul (Deem, 2009).   And in most cases, the embryo is not 
considered the equivalent of a full grown human because Islamic law clearly depicts a difference 
between potential life and actual life (Fazzetto, 2004).  This fact, coupled with the the part of 
Islamic law stating that any preserved embryo can not be used by anyone other than the parents, 
means that the use of unwanted embryos in IVF clinics is supported (Fazzetto, 2004). 
Consequently, research using embryos is supported by most Muslims. 
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However, Muslims do have some issues against cloning.  In the Muslim tradition, family 
relationships and parental love are of extreme importance, making the idea of  cloning these cells 
by SCNT disturbing (Fazzetto, 2004).  The fertilizing of an egg by a sperm is seen as creating or 
validating a relationship between the male and female donors, so the fertilization process, for 
purposes other than helping infertile couples, violates this extremely important set of morals 
(Fazzetto, 2004).  Overall, Islam is divided on the issue—conservative opinions coming from 
Egypt state that the embryo represents an early human life that should not be destroyed, while 
other North American Islamic liberal views believe that since the cells are not part of the body 
they do not hold any potential to become a human life (Deem, 2009). 
 
Hinduism 
Followers of Hinduism believe in reincarnation after death, or a life-cycle consisting of 
birth, death, and rebirth in another form, known as the wheel of life (Griffin, 2010).  In this 
religion, it is believed that all souls merge with the supreme spirit, and to compensate for wrong 
doing many Hindu societies are divided into upper, middle, and lower classes based on spiritual 
purity (Griffin, 2010).  Hinduism teaches that all life, including plants and animals, should be 
considered sacred— so in this sense research using embryonic stem cells is unethical (Bahnot, 
2008).  But an alternative Hindu view states that humans can only survive by consuming and 
exploiting other forms of life (Bahnot, 2008).  Through reincarnation Hindus believe that every 
soul is evolving, from species to species, to reach the human stage and obtain the highest level of 
consciousness in order to reach God (Bahnot, 2008).  Therefore, existing human life is seen by 
some Hindus as more important than human life in the embryonic stage of development.  
Hinduism teaches that it is ethically responsible to help preserve each human life, so adult stem 
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cell research is accepted by a vast majority of the Hindu population  (Deem, 2009).  But for ES 
cells, although prolonging human life is extremely important, the idea of reincarnation means 
that most Hindus see conception as the beginning of human life, so because of this it is not 
generally acceptable to destroy embryos under the constraints of Hinduism (Deem, 2009). 
 
Buddhism 
Buddhist scientists were one of the earliest to isolate human embryonic stem cells 
(Fazzetto, 2004).  Like Hindus, Buddhists also believe in the wheel of life, and that this cycle 
continues until the individual is ready to move on to eternal peace (Griffin, 2010).  Like all of the 
previously mentioned religions, Buddhism supports research on adult stem cells.  However 
Buddhists reject embryo research on the grounds that each embryo contains the essence of an 
individual and, therefore, deserves the same respect as a living person (Fazzetto, 2004).  
However, because Buddhists believe there is no higher power or “divine plan”, the teachings 
actually allow using cloned embryos as nothing prevents it (Fazzetto, 2004).  While some 
ethicists believe that embryo research on pre-mature human beings goes against Buddhist 
teachings, most agree that because individuality is not of extreme importance to Buddhists as in 
other religions, and because it is a Buddhist belief that there are many ways in which life can be 
created, embryo research involving cloning techniques is somewhat acceptable (Fazzetto, 2004).  
It is interesting to see the Buddhist distinction placed between embryos inside the womb, and 
those created outside the body; this suggests that only life created through standard reproduction 
contains a soul. 
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Ethics of iPS Cells 
Induced pluripotent stem (iPS) cells are a relatively new discovery, which many scientists 
hope will provide ES-like cells that are more acceptable to ethicists opposed to embryo research.  
As discussed in Chapter-1, iPS cells are adult skin fibroblast cells treated with specific 
transcription factors to induce de-differentiation to an ES-like state.  Human iPS cells were first 
derived in 1997 using a mixture of four transcription factors (Takahashi et al., 2007), but since 
those early experiments the procedure has been modified to include only two factors (Kim et al., 
2008).  While research with ES cells or SCNT requries embryos, iPS research can be performed 
on any human somatic cell (Baylis, 2008), so iPS cells should have far fewer ethical concerns.  
In addition, eliminating the need for women to donate eggs for SCNT would reduce the chance 
of harm to the donors.   
The main debate with iPS cells is whether they are truly equivalent to ES cells.  Although 
some evidence exists that iPS cells in mice can form a variety of tissues, some scientists claim 
iPS cells are harder to grow (Dolgin, 2010).  iPS cells are at best only pluripotent, not totipotent, 
so they can not develop into a full human organism.  iPS cells lack the organization of an 
ordinary zygote, meaning that if they are implanted they would not develop like an embryo, but 
would develop into more tissues, or in a worst case scenario would develop like a 
teratocarcinoma (tumor) (Cohen and Brandhorst, 2008).  When the growth processes of iPS cells 
and ES cells are compared, there is a huge difference in gene expression in about 1300 genes 
(Deem, 2009).  This means that ES cells and iPS cells are definitely not the same.  So in 
summary, more research will be required to determine whether iPS cells can actually be used to 
treat the same diseases as ES cells. 
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Chapter-3 Conclusion 
Three potential sources of ES cells were discussed in Chapter-1:  blastocysts grown by 
IVF (traditional ES cells), blastocysts grown by parthenogenesis (p-ES cells), and adult stem 
cells that have been induced back to pluripotency (iPS cells).  The author of this chapter supports 
research on all of these stem cells because it is crucial to learn as much as possible about ES cells 
to help ailing lives; the source of these cells is not a huge concern to me.  It is obvious that the 
blastocyst is alive, because all cells are alive.  And I believe that embryos have the full potential 
to become a human life when implanted into the mother‟s uterus.   But an embryo without its 
mother can not develop into a human being and could not survive independently.  As an analogy, 
bread dough has the full potential to become bread, but only if it is baked in the oven; otherwise, 
like discarded embryos, uncooked dough will shrivel up and go to waste.  I believe that any 
embryo, discarded from an IVF clinic or donated for research purposes, should already be 
considered a lost life, from which the harvesting of stem cells seems perfectly ethical.  If the life 
has already been taken away from the embryo, wrongfully or not, its use in stem cell research 
could provide a chance for the lost life to have meaning through helping to save other lives.  
Leaving these beings frozen, forever stuck in their embryonic state, unable to develop, in my 
opinion, is more disrespectful than putting to use the potential they hold.   For those who are not 
comfortable using embryos, scientists have found a way to produce ES cells by parthenogenesis 
or by iPS technology, and I am also in favor of those technologies. 
With respect to SCNT, a type of cloning, I am also in favor of this.  SCNT is the process 
of injecting the nucleus from a patient‟s skin fibroblast cell into an enucleated egg, growing it to 
the blastocyst stage, and isolating ES cells from the inner cell mass whose genetics match that of 
the skin cell donor.  Once this technology has been successful with humans (it only works with 
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mice so far), theoretically ES cells could be derived that are genetically identical to a patient and 
would not be rejected.  Of course cloning has always been a huge red flag in the religious 
community, but I agree with expanding this type of research because it will help increase the 
number of ES cells that scientists have to study, and increase the chance of a successful graft.  By 
creating various types of ES cells and expanding this research, it will help push stem cell 
research toward potential cures for many diseases.  Science already grows human cells, like skin 
cells, for skin grafts for burn patients.  Both SCNT and IVF create embryos solely for research, 
and some think this is unethical.  However, the inability of these embryos to develop and survive 
on their own is important to me.  And with respect to human egg volunteers, during drug testing 
paid human volunteers are often needed for preliminary testing, so this concept of paid 
volunteers is not new.  So I think that clinics and research facilities should be allowed to offer 
paid compensation for any embryos donated for research because, in the long run, the ES cells 
isolated from them will benefit society. 
With respect to iPS cells, the technique is relatively easy to perform, but some studies 
show that iPS cells can be harder to grow than ES cells (Vogel, 2010).  Although the upside is the 
technique produces ES-like cells genetically identical to the patient‟s de-differentiated skin cell, 
the downside is only that patient likely can receive the treatment, others would reject it.  iPS cell 
research, although extremely young, has already had some success in animal implantation trials, 
while ES cells still have not been tested in most applications.  Because of this, I support research 
on iPS cells—they seem to offer real life treatment possibilities for the somewhat near future.  
However, only time will tell whether iPS cells are as medically potent as embryo-derived ES 
cells.  Although I think that iPS cells hold great potential, I also think the scientific community 
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should really push for more funding for embryo research because, after all, they do hold the 
potential to be the most beneficial in the long run. 
One of the most interesting research breakthroughs that I read about during this project 
was the creation of chimeras from the development of human stem cells inside non-human 
subjects, such as mice (Karpowicz et al., 2004).  The ethical concerns surrounding this particular 
type of chimera experimentation were most valid, in my opinion, because they deal with a side of 
science that has not been fully explored.  On the stance that creating inter-species organisms 
defies nature, I believe that as long as we do not allow these animals to reproduce and we do not 
create any new species for habitat population, then science has not defied nature and these 
chimeric animals can teach us something about the ability of various samples of human ES cells 
to grow and differentiate.  The purpose of these types of experiments is solely to test the 
effectiveness and safety of stem cell applications so that real life treatments may one day be 
established for common practices.  I do think that this technique can be disrespectful to the 
species involved, but scientific research has always relied on the use of animal testing before 
applying certain hypotheses to human treatment—and that is extremely important in this case 
since the transplantation of ES cells sometimes causes cancer in the host organism (Karpowicz et 
al., 2004). 
With respect to adult stem cells, they can hopefully be isolated from the tissues of 
patients who need treatment.  These cells are found in the body and can mostly form the type of 
tissue from which they are extracted.  These cells do not offer as much potential as ES cells, but 
they can still benefit the conservative part of society.  I support the use of adult stem cells 
because I think they will always be appropriate in minor cases.  I feel that ES cell usage should 
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not be abused, and the use of adult stem cells should be used whenever possible, or by patient 
request. 
With so many different beliefs on stem cells, it is easy to see how this topic can become 
extremely controversial between scientific and religious communities.  For those who are unsure 
about scientific facts, or those who do not identify with any particular religion, they can still 
form opinions based on personal feelings and education.  When forming an opinion on this topic, 
it is important to remember that there are many different types of stem cells, and many ways they 
can be isolated and grown.  Most people can find at least one type of stem cell research that they 
feel comfortable with, which is important because for any progress to be made, the general 
public must support the scientists who perform the studies. 
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Chapter-4: Stem Cell Legalities 
Harry Hovagimian 
 
 In addition to the stem cell ethical responsibilities faced by scientists and researchers, 
laws have also been enacted to control this controversial technology.  These laws are as complex 
as the ethics inspiring them, and vary by global region and change over time. In the United 
States, each presidential era of the past couple of decades has brought about new embryo and 
stem cell policies, protocols, laws, bills, amendments, and other actions based on their beliefs 
and their parties beliefs.  Each president has either overturned embryo laws created by their 
predecessors or created new laws. 
 When a subject so highly controversial as stem cells is discussed, public opinion helps 
prioritize the regulations, especially for the more controversial topics such as human embryonic 
stem (hES) cells.  These laws govern embryo and stem cell research, and change the way we as a 
society view the use of such cells. 
 
United States Federal Embryo Policies 
While scientific research that led to the discovery of stem cells has been around since the 
early 1960s, monumental laws regulating the use of stem cells in the United States were not fully 
developed until the early 1990s.  After in vitro fertilization (IVF), the excess embryos originally 
created for reproductive purposes are simply discarded by the clinic, so laws must address 
whether these discarded embryos can be used for scientific research. Shortly after the first 
successful human in vitro fertilization in 1969, and legalized abortions (Roe v. Wade, 1973), the 
federal government created regulations that prevented the use of federal funds for research on 
human embryos.  The U.S. government's position controlled only federal funding, but in no way 
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affected or controlled the use of private funds. (Wadman, 1999)  In 1974, President Nixon‟s 
National Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research recommended a ban on all federally funded research using embryos and fetal tissues, 
and the ban was enacted by congress.  These preventative laws were maintained by the Reagan 
and the first Bush administrations due to their strong anti-abortion sentiments. 
 
Clinton Administration: 1993-2001 
The ban on using federal money for embryo research was not reversed until the early 
1990s with the Clinton Administration (Wertz, 2002).  In January 1993, newly elected President 
Clinton reversed the original 1974 Nixon ban on embryo research by passing the National 
Institute of Health Revitalizations Act, which allowed the National Institute of Health (NIH) to 
fund human embryo research (Dunn, 2005). However, this policy caused a backlash in the 
conservative Congress, and the next year they voted to overturn the Revitalization Act, to restore 
the original 1974 ban. 
Shortly after the overturn, NIH created the Human Embryo Research Panel to make 
recommendations to President Clinton.  The Panel eventually recommended the use of federal 
funds to support research on embryos specifically created for experimentation, but in an official 
statement by the president released in late 1994, President Clinton declined to support the 
recommendation, citing potential ethical concerns (Office of the Press Secretary, 1994). 
During the Clinton Administration, a wide variety of scientific advances were made in 
the United States. From the beginning of his presidency, President Clinton showed overall 
support for science and technology research regarding stem cells. President Clinton and vice 
president Gore won respect from researchers during their time in office by not only lifting 
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Federal funding bans, but by disputing Republican congressional leaders‟ attempts to slash 
budgets and insuring growth for science and technology  research. (Malakoff, 2000) 
 
Bush Administration: 2001-2009 
One of the most well-known actions taken by the Bush administration was on August 9, 
2001, when in a nationally televised announcement President George W. Bush announced that he 
would allow the use of federal funds on ES cell research, but only on those ES cell lines created 
before that specific date. This decision limited federally funded U.S. researchers to 60 ES cell 
lines derived from five different countries.  Unfortunately, this original estimate of valid ES cell 
lines proved to be an over-estimate, and subsequent research by Science limited the ES lines to 
about 34 derived from 4 countries (Vogel, Bush Squeezes between the Lines on Stem Cells, 
2001).  This number of allowed ES cell lines eventually declined to around 21, as some were 
contaminated. (Wilson, 2009) 
Throughout his term as president, George Bush vetoed legislation proposed to ease 
restrictions imposed on ES cell research (Babington, 2006).  President Bush often cited moral 
positions behind his decisions, stating that “if a bill does that[destroys life], I will veto it” (Baker, 
2005).  The detrimental effects on U.S. ES cell research from the Bush administration have not 
been fully quantified.  As shown in Figure-4, the percentage of research publications referring to 
human ES cell research decreased during the Bush Administration, compared to other papers 
published in the United States in that era (Schrope, 2009). 
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Figure-4:  Diagram of the Decrease in ES Cell Research Papers in 
the U.S. Under the Bush Administration.  (Schrope, 2009) 
 
Obama Administration: 2009-Present 
During his presidential campaign, Barack Obama promised to prioritize scientific 
innovation, and to separate scientific research from political or moral influences. Obama said the 
majority of Americans supported lifting the federal ban on embryo research, allowing 
researchers to work on cures for things such as cancer, heart disease, Parkinson's, and other 
illnesses (Wilson, 2009). 
Upon entering the Oval Office in 2009, President Barack Obama reversed the eight-year-
old ban on federal funding for stem cell research.  As only 21 of the 60 stem cell lines authorized 
for research under the Bush policy proved to be useful to researchers, Obama's decision to 
overturn this policy was intended to further stem cell research discovery. "In recent years, when 
it comes to stem cell research, rather than furthering discovery, our government has forced what 
I believe is a false choice between sound science and moral values," Obama said at the White 
House (CNN, 2009).  During his presidency thus far, President Obama continues to support this 
policy, but some fear that the topic of stem cell research may possibly just be a pawn in a much 
bigger political game.  Representative Diana DeGette, D-Colo. expressed concerns that stem cell 
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research could become "a pingpong ball going back and forth between administrations." 
Representative DeGette voted on Obama's legislation to become federal law, after failing twice 
in the past to overturn Bush's restrictions (Borenstein & Feller, 2009). 
 
State Laws on Embryo Research 
In contrast to common misconceptions, ES cell research has never been directly outlawed 
federally in the United States, it has only been banned from receiving federal money.  To 
overcome this federal ban, some states have reached out a welcoming hand to scientists 
searching for life-saving discoveries potentially contained within stem cell research.  Those 
states welcoming scientists pursuing these treatments include: New Jersey, California, 
Massachusetts, Connecticut, and others. (Vestal, 2008) 
With respect to Massachusetts, our state has developed legislature funding university 
research centers, business tax credits, state grants, and other incentives aimed at furthering 
Massachusetts as a hub of bioscience and biotechnology (Nature, 2008).  In this state, Senate 
bills number 2039 and 2032 were passed in 2005 which laid forth a solid foundation on which 
the enhancement and development of regenerative medicine within the Commonwealth could be 
built (Harkins, 2005). The bills allowed for research and clinical applications involving the 
derivation and use of hES cells. While these bills opened the field for stem cell research in MA, 
they very carefully laid out some key terms including: specifically stating that any gametes used 
must be donated with consent, human reproductive cloning is strictly prohibited, and it allowed 
the formation of both a Massachusetts stem cell research advisory board of 8 members and a 
biomedical research advisory council of 15 members (The Commonwealth of Massachusetts, 
2005). Senate Bill number 2039 authorized and directed the University of Massachusetts 
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Medical School in Worcester, MA to establish and maintain a public bank for collecting and 
storing umbilical cord blood and placental tissue (The Commonwealth of Massachusetts, 2005). 
These bills also called for a public Institutional Review Board to be formed at UMMS in 
Worcester. The University of Massachusetts Medical School is also currently constructing a 
500,000 square foot facility, known as the Albert Sherman Center, which will hold the Center for 
Stem Cell Biology and Regenerative Medicine, a facility which will become the world's largest 
repository for ES cell lines (Marks, 2007). 
With respect to other states, in January 2004, the state of New Jersey was the first to fund 
ES cell research by designating $10 million to such research.  This was followed shortly 
thereafter when in November 2004, California established a voter approved $3 billion fund. 
(Vestal, 2008).  Shortly after Massachusetts approved its bills in 2005, the neighboring state of 
Connecticut developed their own strategies involving ES cell research that included a 10 year 
$100 million plan (Internet Broadcasting Systems Inc., 2005).  Other US states have also taken 
very clear sides on the stem cell research debate. While many states avoid this controversial 
topic, 14 other states have either banned ES cell research altogether, or ensured legality, with 
some of those states going so far as to independently fund ES cell research, as seen in Figure-5. 
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Figure-5:  Diagram of U.S. States ES Cell Policies. (Vestal, 2008) 
 
International Stem Cell Policies 
The stem cell research technology race is not limited to the United States. Many countries 
throughout the world are the homes of leading researchers and students in the field of stem cell 
research and regenerative medicine. Unlike the United States government which technically 
allows all forms of ES research (except reproductive cloning) and controls it through federal 
spending, countries throughout the world either have strict policies which restrict or prohibit 
stem cell research, or they welcome the science and actively fund such innovation (Vestal, 
2008). 
South Korea announced in 2005 the creation of the World Stem Cell Foundation in 
Seoul, intended to produce approximately 100 new ES cell lines each year.  Initially, the hope in 
creating this stem cell bank was to sidestep President Bush‟s restrictive policies in the U.S. to 
provide U.S. researchers with ES cell lines derived outside the U.S. (Kaplan, 2005). 
In Japan, ES stem cell research was allowed from guidelines approved in 2001. While 
this sounded promising, as it allowed scientists to derive new hES cell lines and research both 
homegrown and imported lines, it required an approval process that was eventually shown to 
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stifle the amount of research performed. In 2009, The Japanese Council for Science and 
Technology Policy pushed new regulations intended to remove some of these burdensome 
restrictions (Cyranoski, Japan relaxes human stem cell rules, 2009).  In 2007, Shinya Yamanaka 
of Kyoto University created the world‟s first induced pluripotent stem (iPS) cell (Takahashi, et 
al., 2007) Unfortunately, due to a lack of legal expertise in this field, Kyoto University stalled 
over developing a strategy to protect its patents in this very lucrative area.  In Japan, patents are 
usually awarded to researchers who file first,  as opposed to the laws in the United States where 
patents are awarded to those who can prove they discovered something first.  This example of 
the concern over patenting and intellectual property rights of therapeutic stem cell research 
shows that this is not just a research race, but more of a race to the commercialization of the 
technology (Cyranoski, Japan ramps up patent effort to keep iPS lead, 2008). 
European countries tend to vary on their ES cell policies, like various US individual 
states. In Sweden, embryo research is allowed based upon a law passed in 1991, and the Swedish 
government has funded at least two labs deriving human ES cell lines. While the Swedish 
Research Council has reported that some loopholes need to be closed, as there are no laws 
currently preventing human reproductive cloning in that country, Sweden is far less politically 
charged than some other countries (Vogel, Germany Dithers over Stem Cells, While Sweden 
Gives Green Light, 2001). Most recently, Sweden has allocated SEK 100 million for 
regenerative and stem cell research (Karolinska Instituet, 2010).  Other European countries, such 
as Germany, have regulations controlling the importation or utilization of hES cells. In 2002, 
German Parliament enacted a ban on creating and working on hES cell lines; stem cells 
harvested abroad prior to the cutoff date of January 1, 2002 were allowed to be imported into the 
country (Kim, 2002).  In 2008, an amendment to the German Stem Cell Act of 2002 changed the 
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cutoff date on importation of ES cell lines to those created before May 1, 2007 (Herrmann, 
Woopen, & Brüstle, 2008). 
 
Chapter-4 Conclusion 
As stem cell research continues to grow, both in the United States and across the world, 
laws will continue to change and grow with the technology. In order to remain a leader in stem 
cell research, the U.S. federal laws governing stem cell research need to stay on one path, and 
not be created based upon a president's own personal moral views.  The authors of this IQP share 
the concerns of U.S. Representative DeGette that stem cell research could become “a pingpong 
ball going between administrations,” as has been seen in recent presidencies. The United States 
could be considered one of the better countries for conducting stem cell research, as federal laws 
have never outright banned the research (just prevented it from receiving federal funding), but 
the laws have controlled the major funding, and have left the responsibility in regards to legality 
to the discretion of the individual state government. While some states have gone the route that 
some countries have in banning the research, other states have done their best to ensure the 
legality and funding of such research, and hopefully the research and breakthroughs in these 
supportive states will eventually positively influence other states. 
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Project Conclusions 
 
The stem cell debate is fueled by a lack of accurate information for many people, and by 
a variety of opinions on embryonic stem (ES) cells and the techniques used to derive them.  
While there may never be a clear universally accepted ethical answer on whether it is acceptable 
to work with embryos and ES cells, the technology continues to advance.  Thus, it is important to 
form guidelines that serve the interest of both religious communities and those directly involved 
with the science.  The following section is an overview of the how the authors of this IQP project 
feel about the main components of the stem cell debate. 
While the authors of this report believe that the use of ES cells should continue, these 
cells should not be abused; their use should be limited to serious cases, like the treatment of 
Parkinson's and Alzheimer's disease.  In the meantime, adult stem cells (ASCs) should be used 
wherever possible as alternative treatments to those opposing ES cells, as ASCs are more 
acceptable ethically.  Of the three types of ES cells: traditional ES cells, parthenote-derived ES 
cells (p-ES cells), and induced pluripotent cells (iPS cells), the authors support all types for 
further research and eventual medical use.  In regards to the destruction of embryos, the authors 
recognize that IVF embryos do have the full potential to become a human life when implanted 
into the mother‟s uterus.  However, an embryo without its mother cannot develop into a human 
being, so its destruction is not seen as unethical by the authors.  For those embryos which have 
been discarded by IVF clinics, they should undoubtedly be used for research, with donor 
consent.  The unwanted life represented by every excess frozen embryo also has the potential to 
save human lives through their ES cells.  In addition, the authors support the creation of embryos 
solely for research purposes, as it allows those who fully support ES cell research to really 
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participate in the advancement of technology.  With respect to other techniques for obtaining ES 
cells, the authors support any research for producing ES cells, including parthenogenesis or 
induced pluripotency, as well as SCNT (cloning).  SCNT should eventually eliminate stem cell 
implant rejection, as the cells will be genetically identical to the skin cell nucleus donor.  
Overall, more funding for ES cell research is needed because this is an extremely promising 
technology that could potentially improve the quality of or save the lives of millions. 
With respect to laws regulating stem cell use, it is important to have guidelines that 
satisfy both those who are against ES cell research and those who support it.  The United States, 
now that Obama has entered the Presidency, has a very good approach to regulating stem cell 
research in a way that respects most members of the population.  Chapter 4 mentions that Obama 
has made it possible for some labs to get federal funding for the creation and study of ES cell 
lines, which was impossible under the Bush Administration.  However, as a nod to those who 
oppose the research, only certain ES cell lines can be used in labs receiving federal funding; the 
ES cell lines must pass stringent NIH guidelines for embryo donations from IVF clinics, must be 
created only for reproductive purposes, and cannot be created solely for research purposes.  The 
IQP authors support the former stance, but not the latter. While the federal government will fund 
ES research under certain conditions, it still allows for each state to derive its own laws on 
whether this research will be funded locally.  This shows that the government supports and 
appreciates this great technology, but also understands the need for strong oversight.  The 
authors support the overall Obama approach, and feel it is very democratic and favorable in the 
upholding of civility, peace, and the respect of divided public opinions. 
